Continued strong enrollment of pivotal Phase 3 global study evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 on track to complete enrollment by year end 2023
Company anticipates. -Today at 08:13 am- MarketScreener
Cyclo Therapeutics Stock (NASDAQ:CYTH), Quotes and News Summary benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
The Dow Jones closed lower by around 350 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Contrasting Adaptimmune Therapeutics (NASDAQ:ADAP) & Cyclo Therapeutics (NASDAQ:CYTH) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.